| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 25.05.
| Progenics Pharma: Several Short Term Catalysts With Good Long Term Fundamentals | | - | Seeking Alpha |
| 21.05.
| Progenics Pharmaceuticals Earnings In Retrospect: Down 21.3% in the Last 13 Days | | - | SmarTrend |
| 11.05.
| Progenics Pharmaceuticals Has Returned 36.2% Since SmarTrend Recommendation | | - | SmarTrend |
| 08.05.
| PROGENICS PHARMACEUTICALS INC - 10-Q, Quarterly Report | | 1 | SEC Filings |
| 03.05.
| Uptrend Call Working As Progenics Pharmaceuticals Stock Rises 51.6% | | 2 | SmarTrend |
| 25.04.
| Salix, Progenics Announce FDA Extension Of RELISTOR SNDA Goal Date To July 27 | | 59 | AFX News |
| WASHINGTON (dpa-AFX) - Salix Pharmaceuticals, Ltd. (SLXP) and Progenics
Pharmaceuticals (PGNX) announced that the Food and Drug Administration, or FDA,
has extended the Prescription Drug...
Mehr lesen zu:
Salix, Progenics Announce FDA Extension Of RELISTOR SNDA Goal Date To July 27 | |
| 25.04.
| Salix (SLXP), Progenics (PGNX) Get FDA PDUFA Extension Date for RELISTOR | | - | StreetInsider.com |
| 25.04.
| Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012 | | 29 | Business Wire |
| Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals
(NASDAQ: PGNX) today announced that the Food and Drug Administration
(FDA) has extended the Prescription...
Mehr lesen zu:
Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012 | |
| 24.04.
| The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals | | 42 | PR Newswire |
| CHICAGO, April 24, 2012 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals | |
| 12.04.
| Progenics Pharmaceuticals Has Returned 46.4% Since SmarTrend Recommendation | | - | SmarTrend |
| 04.04.
| Progenics Pharmaceuticals Shares Up 45.7% Since SmarTrend's Buy Recommendation | | - | SmarTrend |
| 02.04.
| Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Progenics Pharmaceuticals Is Up 5.4% | | 2 | SmarTrend |
| 20.12.
| Salix, Progenics Shares Rise On Positive Constipation Drug Study Results | | 68 | AFX News |
| WASHINGTON (dpa-AFX) - Shares of Salix Pharmaceuticals Ltd. (SLXP) and
Progenics Pharmaceuticals Inc. (PGNX) rose on Tuesday, after Salix reported a
successful late-stage trial of oral methylnaltrexone...
Mehr lesen zu:
Salix, Progenics Shares Rise On Positive Constipation Drug Study Results | |
| 20.12.
| Salix, Progenics Report Results Of Phase 3 Trial Of Oral Methylnaltrexone | | 40 | AFX News |
| WASHINGTON (dpa-AFX) - Salix Pharmaceuticals, Ltd. (SLXP) and Progenics
Pharmaceuticals, Inc. (PGNX) announced the successful outcome of the Phase 3
trial to assess the efficacy and safety...
Mehr lesen zu:
Salix, Progenics Report Results Of Phase 3 Trial Of Oral Methylnaltrexone | |
| 20.12.
| Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation | | 39 | Business Wire |
| NDA Submission Targeted for Mid 2012
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals,
Inc. (NASDAQ:PGNX) today announced the...
Mehr lesen zu:
Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation | |
